The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more than 50% of all oncologists practising in the US, Chicago-based Tempus ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

In oncology, the Tempus algorithmic test platform leverages its molecular and clinical database, CAP/CLIA lab and clinician network to develop tests that help inform the treatment of cancer patients.

Tempus is a cancer diagnostics company that provides genomic testing results. Tempus has also amassed an over 200 petabyte proprietary multimodal dataset that combines clinical patient data with ...

(RTTNews) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced ... as part of the standard of care—not just in cancer, but in cardiology, neurology, immunology, and every other ...

Tempus AI, a health tech firm ... Ambry specializes in genomic testing for inherited cancer risk. The acquisition closed in February. Turning to its balance sheet, as of December 2024, cash ...

"By expanding our collaboration with Illumina, we are combining our strengths in technology and data analytics with their strengths in developing new sequencing technologies to drive forward ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... which includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research ...